
### S.O.S ONCOLOGY

#### Giovedì, 24 ottobre 2024

Sala Biagi, Palazzo Lombardia



**Dr. Federica Albanese, PhD** Scientific Officer

In collaborazione con




Sistema Socio Sanitario






#### **Regional Foundation for Biomedical Research**




#### **Early Career Award- II edition**

#### Definition of «young researcher» :

- no more than 8 years of experience after PhD degree or medical residency;
- Maximum 40 years old;







Regione Lombardia

#### **Consensus Meeting**







#### **Speakers**

#### Prof. Pedro Castelo-Branco, PhD



President of the Algarve Clinical Academic Centre Portugal

#### Prof. Triantafyllos (Lakis) Liloglou, PhD

Director of the CardioRespiratory Research Centre Edge Hill University UK








### S.O.S ONCOLOGY

#### Giovedì, 24 ottobre 2024

Sala Biagi, Palazzo Lombardia



Fondazione IRCCS Istituto Nazionale dei Tumori

In collaborazione con

- Sistema Socio Sanitario





### Writing a successful grant application

**Pedro Castelo Branco Lakis Liloglou** &









**Medical School** 





### Who are we?



Today's aim

# Assist you in writing grant applications with a higher chance of success



#### **Grant application process**

Submit grant			
Submit grant			
Submit grant			
Submit grant	Need to convince the reviewers		
Submit grant	Peer review	Grant committee	<ul> <li>Priority list</li> </ul>
Submit grant			
Submit grant			
Submit grant			
Submit grant			Awards based on available budget



#### **Convince reviewers about what?**

- This is research that is worth doing
- You have a solid research plan in mind
- The research team has the expertise
- The environment can support the project



#### This is research that is worth doing

- You have a clear and precise research question / hypothesis
- The focus of research is a significant problem
- For translational research -> addressing a clinical problem
- The phrase is "clinical unmet need"
- There is a knowledge gap that your proposal will fill
- The research output has high chance to benefit healthcare



#### **Translational research**

#### Utilise

- Patient populations (ex vivo)
- Animal models, xenografts etc (in vivo)
- Cell culture, organoids etc (in vitro)
- Combinations of above

#### look for

- Biomarkers of clinical outcomes
- Mechanistic studies
- Intervention effect on cells
- Genetic/epigenetic impact on intervention response
- Combinations of above



#### You have a solid research plan in mind

- Study design
- Study size
- Bias reduction

#### Maximise internal and external validity

• Research planning and time management



#### Study design

Your study design can facilitate the Research Question /Hypothesis

Your starting point

Population Intervention (or exposure) Control(s) Confounding factors Outcome(s) Measurable (T)ime Measurable Widely accepted



**Study designs** 

#### Observational

#### Interventional / Experimental

Can produce associations ONLY

Can indicate causation

#### **Descriptive** Analytical

Hypothesis generating

Hypothesis testing

Hypothesis testing



#### Aims, Objectives, Outcomes & Endpoints

Aim: what do I want to demonstrate

Objectives: How am I going to demonstrate it (break down to components)

Outcomes: The measured variables used to quantify the objective

Endpoints: The point along the outcome measure that defines a significant biological or clinical function (physiological or pathological)


Make these **clear** – potentially bullet points – **do not hide** them in rows of text.



#### **Design and define your "killer experiment" !**



#### **Organise** <u>research</u> WPs (if applicable)



#### **Ensure WP cohesiveness and low inter-dependency**



#### Study size & statistical power

### How many subjects are enough?

#### Hypothesis testing: Type I / Type II errors

The **null hypothesis (H<sub>0</sub>)** is that there is **no difference** between the entities (groups/treatments/etc) compared

The alternative hypothesis  $(H_1)$  is that there is a difference between the entities (groups/treatments/etc) compared

A type I error (alpha) occurs when we reject the null hypothesis incorrectly (i.e., there is no difference between the two groups but we conclude there is difference (false positive conclusion)


A type II error (beta) occurs when we accept the null hypothesis incorrectly (there is a difference between the two groups but we conclude that there is no difference (false negative conclusion).



**Statistical power** 

### Power = $1-\beta$

#### Minimum power acceptable: 0.8 or 80%




Seminar for early career applicants, Milan 24 Oct 2024



#### Have a statistician on board at the proposal design




#### **Create a story line: Proposal**





#### **Scientific writing**



#### **Knowledge & comprehension**

content



#### Have a realistic time plan to write it





#### Be prepared for A FEW drafts





#### Interact with your mentor(s)












#### So, you have an idea for research



What is the first thing to do?




### Search the existing literature






#### Basic elements of my Research Question/Hypothesis










## Qualitative research


# Quantitative research




## **Research Study levels**



Proof-of-concept study





Roadmap to a Quantitative Research Proposal



Work on examples

### Please share research questions to discuss



# Thank you



#### Questions



Category: PRINCIPAL INVESTIGATOR (PI) – TRACK RECORD	Maximum score: 20
Ability of the PI in conducting research projects in a creative and independent manner, as demonstrated by previous experiences	0-10
Scientific skills of the PI necessary to successfully implement the proposed project	0-10
Category: EXCELLENCE OF THE PROJECT PROPOSAL	Maximum score: 20
Clarity and relevance of the proposed objectives	0-10
Soundness of the hypothesis and of the preliminary data, credibility of the proposed methodology, ethical aspects included	0-10
Category: IMPACT OF THE PROJECT PROPOSAL	20
Possibility of the project to contribute to the advancement of scientific knowledge, beyond the state of the art, in the related research area	0-10
Quality of the proposal in terms of: – Dissemination to and sharing of results with the scientific community	0-10
<ul> <li>Dissemination of results to the lay public</li> <li>Description of Responsible Research and Innovation principles (RRI)</li> </ul>	
Category: QUALITY AND EFFICIENCY OF THE PROJECT PROPOSAL	Maximon score:
Quality and efficiency of the workplan, adequacy of the budget and of the resources allocated to each work package in line with the project objectives	0-10
Appropriateness of the technical infrastructures and of the management of the project	0-10

#### **REFLEXION !!!!**



Category: PRINCIPAL INVESTIGATOR (PI) – TRACK RECORD	Maximum score: <b>20</b>
Ability of the PI in conducting research projects in a creative and independent manner, as demonstrated by previous experiences	<mark>0</mark> -10
Scientific skills of the PI necessary to successfully implement the proposed project	0-10

- Funded projects; Masters and PhD Students projects
- Publications (1st, last and/or corresponding authorship)

#### THIS IS ABOUT WHO YOU ARE SO PET YOUR CV !!!!





Category: EXCELLENCE OF THE PROJECT PROPOSAL	Maximum score: <b>20</b>	
Clarity and relevance of the proposed objectives	0-10	
Soundness of the hypothesis and of the preliminary data, credibility of the proposed methodology, ethical aspects included	0-10	


- If needed number your objectives (clarity). Relevance comes from your line of study.
- Make the hypothesis very very clear.
  - Ex...based on the presented case **WE HYPOTHESIZE** that...
  - Priliminary data supporting the project, show it, do not only list published papers...
  - Link the methods with the technologies to be used.
  - Please do not forget ethics. If ethical considerations are not an issue, state it!!!



Category: IMPACT OF THE PROJECT PROPOSAL	Maximum score: <b>20</b>	
Possibility of the project to contribute to the advancement of scientific knowledge, beyond the state of the art, in the related research area	0-10	
<ul> <li>Quality of the proposal in terms of:</li> <li>Dissemination to and sharing of results with the scientific community</li> <li>Dissemination of results to the lay public</li> <li>Description of Responsible Research Innovation (RRI) principles</li> </ul>	0-10	THIS HAS TO BE A 10!!!

• Advancement of the scientific Knowledge – it comes from your hypothesis and objectives that will lead to the expected impact.





- Workplan: link the work packages with the people in the team
- Budget: link it with the work packages and objectives
- Add a work chart



**Project title** 

Ex: The role of PTB binding to Shc and IRS-1 in a phosphotyrosine-dependent fashion to peptides that form a b turn.

WHAT IS WRONG?



#### Project acronym

#### **Ex EPI-PTB-NUC**

#### WHAT IS WRONG?

### Free AI Acronym Generator

ooking for an easy way to generate acronyms? Try our I Acronym Generator today and streamline your vorkflow.

Get acronyms for	Generate	
<u>The</u> role <u>of</u> sugar in <u>hypertension</u>		5 variants v
	🕂 Generate Acronyms	
299 characters · 44 words · English	ı∆ ⊽ <sup>ı</sup> ×	
1. SUGAR: Sugar's Unseen Grip on Arterial Resist	tance	
2. SWEET: Sugar's Weighty Effect on Elevated Te	ension	
3. HYPER: Hypertension Yielding from Poor Eatin	ng Regimens	



Total requested budget (MAXIMUM 1,000,000 EUROS)

Ex: 1,000,000 Euros

Ex: 999973 Euros

WHAT IS WRONG?

EX: 900,000 Euros for Human Resources is requested...

WHAT IS WRONG?

Your buggest should be balanced...



**Preliminary data** 

- > Show only what is directly relevant for the proposal.
- > Published work that supports your project is ok to be mentioned in the text.
- > There is a difference between preliminar data and previous data...



**Figures and tables** 

Very often figures and tables are shown with poor quality and overly crowded. Reason might be the conversion of files. Test this in advance!!!



 In agnostic approaches, have no independent discovery (training) and validation (test) groups

• For outcome prediction, not to calculate **PPV** and **NPV**, but stick with sensitivity and specificity

• Put all the weight in p-values and miss the **effect size** 



## **Common mistakes in data analysis**

- Use means and parametric tests for continuous variables that do not fit normal distribution
- Use p-value in correlation tests (Pearson's / Spearman's) as an indication of significant correlation



#### Research hypothesis and specific aims

Describe here how the proposal fits the scope of the call,

the personalized medicine dimension of the proposed work,

the rational,

specific objectives and the overall strategy of the proposed research,

highlighting the novelty and feasibility,

and the potential impact of the project results on health care.

Max 2.000 characters including spaces.

#### Often part of what is asked is not addressed.



#### **Experimental plan (work packages)**

Report, for each work package (WP): (a) the WP number and title (max. 5 WPs),

(b) its objective(s),

(c) tasks, and related activities,

(d) methodology used,

(e) milestones1 (max. 2 milestones for each WP),

(f) expected results and deliverables2 (max. 2 deliverables for each WP),

and (g) a contingency plan to mitigate any pitfalls and caveats. After each WP describe feasibility and contingency

In case of clinical studies/trials a scheme of the study design must be provided (max. 1 page).

... for projects involving clinical trials, enrolment of patients and/or healthy subjects

and/or the collection of human material and/or data, approval(s) by the Competent Regulatory Authority.

are due before the project start. Therefore, the achievement of such approval(s) cannot be a milestone or a deliverable.

Note: A translational oncology project has to have some of these materials. Show the status of ETHICAL APPROVALS.

#### > Often part of what is asked is not addressed.



#### Gantt chart

Insert here the Gantt chart. The Gantt must report the WPs as described in section X, their duration (in months), the milestones described in section Y and the deliverables described in section Z.

Activity	GY1				GY2			
	Q1	Q2	Q3	Q4	Q5	Q6	Q7	Q8
• Develop items for survey								
<ul> <li>Review and revise items with experts' panel.</li> </ul>								
<ul> <li>Pre-test items with representative sample of target population.</li> </ul>								
<ul> <li>Program software to administer survey.</li> </ul>								
• Prepare survey sites for study.								
Recruit and train Study Reps.								
<ul> <li>Recruit 1,000 subjects and administer survey at 5 sites.</li> </ul>								
<ul> <li>Statistical analysis of data.</li> </ul>								
<ul> <li>Preparation and submission of manuscripts to peer-reviewed journals.</li> </ul>								

#### WHAT IS WRONG?



- Potential impact of expected project results on the regional healthcare system, patient wellbeing and personalized medicine advancement.
  - Needs to be very clear. If your project is not really translational you will have a hard time writing this up.
     Outcomes need to have impact in the "near future". Therefore combining basic scientists with clinicians is fundamental.



- Dissemination and communication plan/activities
  - To the scientific community
  - To the society in general
  - Educational programs

> Often part of what should be addressed is not.



- Implementation of Responsible Research and Innovation (RRI) principles
  - PUBLIC ENGAGEMENT
  - GENDER EQUALITY
  - SCIENCE EDUCATION
  - ETHICS
  - OPEN SCIENCE
  - GOVERNANCE

- READ THE DOCUMENT!!!!
- ADRESS EACH ISSUE SEPERATLY IF POSSIBLE!!



#### • Project management and infrastructures

- Describe how the project will be managed,
- the scientific environment in which the research will be done
- ... and any institutional facilities,
- resources and equipment available to the PI and the research team.

- MANY TIMES THE MANAGEMENT STRUCTURE IS MISSING OR NOT CLEAR...
- STATING THAT YOU WORK AT A WIDELY ACCLAIMED CENTER IS NOT ENOUGH!
- MATCHING FACILITIES AND EQUIPMENT WITH THE TEAM MEMBERS IS A GOOD IDEA...



## What reviewers like

- Any issues or limitations in your study? If yes what is your contingency plan?
- No mistakes!
- Final statment: Why is your proposal very importante?
  - How will you improve the knowledge?
  - Are you opening a new way of dealing with the problem?
  - Who will you help and how?
  - Any economical considerations?



## What reviewers like

#### • Preliminary Data in Support for the Current Proposal: Clinicopathologic characteristics


haracteristics	Number of patients $N = 35$	Percentage (%)	Variable	Mean±SD	Median (25–75% IQR)	No of patien
	66 (42-82)		valiable	INIE dil ± 5D	(2J-7J/0 IQK)	pauen
				62 42		405
ale	23	66	Age (years)	63±13	66 (57–73)	105
emale or location	12	34	Male gender			67 (64
entral	9	26	-			
orsal	5	14	NYHA class III/IV			51 (4
terally to the right	12	34	BMI (kg/m <sup>2</sup> )	24±4	23 (21–27)	105
erally to the left	9	26				
cteristics of the procedure	20	20	Systolic BP (mm Hg)	130±25	130 (112–145)	105
w anterior resection loanal resection	28 2	80 5.5	Diastolic BP (mm Hg)	75±17	72 (63–84)	105
rtmann's operation	3	8.5				
ctal amputation	1	3	Heart rate (beats/min)	73±14	70 (61–81)	105
ersphincteric resection	1	3	Haemoglobin (g/dl)	13.1±2.0	13.2 (12.0–14.7)	105
of procedure						
paroscopic assic	27	77 8.1	Serum creatinine (mg/dl)	0.97±0.28	0.93 (0.76–1.13)	105
nversion	3	8.5	eGFR (ml/min/1.73 m <sup>2</sup> )	60±16	59 (48–71)	105
botic-assisted	2	6				
(y)pT			Corrected calcium (mg/dl)	9.4±0.4	9.4 (9.2–9.7)	105
	2	6	Inorganic phosphorus (mg/dl)	3.6±0.5	3.7 (3.3–3.9)	105
	8	23 54				
	19 6	54 17	Magnesium (mg/dl)	2.1±0.2	2.1 (1.9–2.2)	105
	0	0	Haemoglobin A1c (%)	6.2±1.1	6.0 (5.5–6.6)	105
(y)pN	•	•		72.24		105
	29	83	Uric acid (mg/dl)	7.2±2.4	7.2 (5.3–8.4)	105
	6	17	PTH (pg/ml)	46±25	40 (31–56)	105
	0	0		402 470		
invasion of blood vessels hoangioinvasion	0	0 14	BNP (pg/ml)	$403 \pm 479$	203 (59–613)	105
eural propagation	1	3	ACE inhibitors/ARB			81 (77
1ª			β Blockers			2E /23
gative > 1 mm	32	91.5	p blockers			35 (33
sitive $\leq 1 \text{ mm}$	3	8.5	Calcium channel blockers			26 (2
nnot assess (ypT0, Dworak 4) rectal excision quality	0	0	Loop diuretics			59 (56
ectal excision quality	17	48.5				
	10	28.5	Aldosterone blockers			31 (30
	8	23				
of mesorectal excision			ARB, angiotension receptor bloc			
E	26	74	peptide; BP, blood pressure; eG	FR, estimated g	lomerular filtration rate	; NYHA,
ME	9	26	New York Heart Association: PT	H. intact parath	vroid hormone	

<sup>a</sup> pCRM = circumferential resection margin assessed by the pathologist.



## What reviewers like

• Project overview





## What reviewers don't like

- Preliminary data (non-published) is different from previous data (published).
- Don't state that your idea is new if it is not!!! If your idea is based on something already known, state what is different.
- Can't find a figure reference in the text...
- Figures that are so dense that one can't read it. Figures, like in papers need to be self explanatory and visualy acceptable.
- To presente a different Grant structure to that in the call.



## **General Recommendations**

- Aim 1 should be almost done (supported by preliminar data)
- Optional material is not an option
- Some people use **bold** in the text. Nice idea but use it with care!!!
- Translation goes beyond cell line work (2D alone not very sexy at the moment)
- Imagine your reviewer as somone very busy, so you need to capture his/her attention all the time.
- You should not right a translational oncology project without an Oncology clinician in the team.
- You should not right a translational oncology project without a basic scientist in the team.



# Thank you



#### Questions